Each year, an intense series of alternative investment conferences take place in and around Miami. Here are the events for 2024 (and some notable changes).
By Ed...
Beyond Marketing Helps Transform Mental Health, TMS & Ketamine Practices into Thriving Businesses.
The way patients behave and think is rapidly changing. Treatment centers, clinics...
MDMA therapy company Lykos raises $100M in Series A funding as it eyes FDA approval (MarketWatch). MAPS Public Benefit Corp. changes name to Lykos Therapeutics.
INVESTORS...
-Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidates
-Two patent-protected,...
Fireside Project was born at a unique moment in history. It was the spring of 2020. The pandemic was raging. Depression, anxiety, and loneliness were at all-time highs. Calls to...
Donation is believed to be ‘biggest that we’ve ever seen in the psychedelics space.’ Quest for treatments for depression, PTSD centers on MDMA, psilocybin and similar drugs.
Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, gives the keynote address "Ketamine for Suicidal Depression: The Benefits are Clear, but so are the Risks." Sachs...
